Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to $88.5 million.

  • ARS Pharmaceuticals' Change in Acquisitions & Divestments rose 45.08% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 19.12%. This contributed to the annual value of $258.0 million for FY2024, which is 39.46% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $88.5 million for Q3 2025, which was up 10.62% from $80.0 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $88.5 million during Q3 2025, with a 5-year trough of $20.0 million in Q1 2023.
  • In the last 3 years, ARS Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $61.0 million in 2024 and averaged $61.4 million.
  • Data for ARS Pharmaceuticals' Change in Acquisitions & Divestments shows a peak YoY soared of 175.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows ARS Pharmaceuticals' Change in Acquisitions & Divestments stood at $60.0 million in 2023, then increased by 11.67% to $67.0 million in 2024, then soared by 45.08% to $88.5 million in 2025.
  • Its last three reported values are $88.5 million in Q3 2025, $80.0 million for Q2 2025, and $63.5 million during Q1 2025.